C5AR1 and COVID-19: Multinational randomized controlled trials of the C5a monoclonal antibody, BDB-001 in China (2020L00003) and IFX-1 in Europe (NCT04333420), are already enrolling patients with severe and critical COVID-19 [23, 36, 37].